Indiana University

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).

890 total trials 156 currently recruiting 561 completed top decile by trial count

Indiana University: 890 sponsored US clinical trials, 156 recruiting.

Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.

Top-decile sponsor footprint

Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 43/100

561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

890 total, page 11 of 18

COMPLETED

Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions

NCT03213951

TERMINATED NA

A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver

NCT02966223

COMPLETED

Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism

NCT03404635

COMPLETED NA

Effects of Soccer Heading on Ocular-motor Function and Blood Biomarker

NCT03488381

COMPLETED NA

Patient-Centered Decision Support to Improve Diabetes Management in Pre-Teens and Adolescents With Type 1 Diabetes

NCT03084900

COMPLETED NA

Comparing Interventions to Increase Colorectal Cancer Screening

NCT03200366

TERMINATED NA

Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT

NCT03116139

COMPLETED Phase 2

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

NCT03136198

COMPLETED NA

Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis

NCT03098082

COMPLETED NA

Task-specificity for Locomotor Recovery Following SCI

NCT03144388

TERMINATED NA

Improving Functional Ability in Chronic TBI With Intensive Rehabilitation Robotic Gait Training

NCT03438409

COMPLETED Early Phase 1

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

NCT03202511

TERMINATED NA

Examining the Effects of Processed Music on Chronic Pain

NCT03083977

COMPLETED NA

Amnion-Chorion Allograft Barrier Used for Root Surface and Guided Tissue Regeneration

NCT03095976

COMPLETED NA

A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy

NCT03338062

TERMINATED NA

Health Information Technology to Improve Bedtime Media Use in Children

NCT03177421

TERMINATED Phase 2

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

NCT02885324

COMPLETED NA

iMETX (Individualized Metabolic RX): a Pilot Study

NCT03158519

COMPLETED NA

Mindfulness to Enhance Quality of Life and Support Advance Care Planning

NCT03257007

COMPLETED NA

G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis

NCT03980145

TERMINATED

Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer

NCT02117440

COMPLETED

Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study

NCT03132337

COMPLETED NA

Reactions to E-cigs and Alcohol

NCT03449017

COMPLETED

Late Function After Surgery for Transposition of the Great Arteries

NCT03078413

COMPLETED NA

Mobile Critical Care Recovery Program for Acute Respiratory Failure Survivors

NCT03053245

COMPLETED NA

Translating 3-Step Workout for Life in a Local Senior Living Community

NCT03095534

COMPLETED NA

Mobile Enhancement of Motivation in Schizophrenia

NCT03059771

COMPLETED NA

Cognitive Intervention to Improve Memory in Heart Failure Patients

NCT03035565

TERMINATED NA

Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial

NCT03009110

COMPLETED Phase 3

Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.

NCT03151434

COMPLETED Phase 1

A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation

NCT02685098

COMPLETED NA

Addressing Place and People Micro Environments in Weight Loss Disparities

NCT03083964

TERMINATED NA

Assessing Outcomes in ED Patients With RV Failure

NCT03073629

COMPLETED NA

Evidence-based Diagnosis and Management of Pediatric Obstructive Sleep Apnea in Primary Care

NCT02781376

TERMINATED Phase 4

Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses

NCT03040323

COMPLETED NA

Decreasing Delirium Through Music

NCT03095443

COMPLETED Phase 1

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

NCT02341274

COMPLETED NA

Scheduled Awakenings for the Treatment of Nocturnal Enuresis

NCT03047720

COMPLETED

Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center

NCT02898337

TERMINATED NA

IU Health Krannert Personalized Medicine Study

NCT02955121

TERMINATED

Glycosylation of Exosomes in Prostate and Urothelial Carcinoma

NCT04960956

COMPLETED NA

Mechanisms of Active Music Engagement to Improve Health Outcomes of Children With Cancer and Parents

NCT03085927

COMPLETED Phase 2

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

NCT02829957

COMPLETED

Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome

NCT02981888

COMPLETED

Pharmacokinetics (PK) and Modeling of Betamethasone Therapy in Threatened Preterm Birth

NCT02793700

COMPLETED Phase 2

Chlorthalidone in Chronic Kidney Disease

NCT02841280

COMPLETED NA

Leg Thermotherapy for Intermittent Claudication

NCT02770547

COMPLETED NA

Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region

NCT02780648

COMPLETED Phase 4

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940

TERMINATED Phase 2

Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

NCT02712788

← Previous Page 11 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 56
Phase 2 70
Phase 3 28
Phase 4 76

What is open in the Indiana University pipeline

156 recruiting of 890 indexed (18% open); 561 completed (63%).

Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).

Top condition: Alzheimer Disease (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Indiana University: open-pipeline peers nationwide

Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Indiana UniversityUniversity of California, Los AngelesHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterEdwards LifesciencesUniversity of South FloridaVA Office of Research and DevelopmentConvaTec
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 890 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Indiana University page

890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.

  • 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Indiana University pipeline card: 890 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.